COVID-19 Vaccination survey shows 84% of users willing to take Covid-19 Vaccination; side-effects primary concern for others. The online survey was conducted across sample size of 30392 by 1mg and BRIEF.
As per the latest survey by 1mg.com, India’s leading healthcare platform, and BRIEF, research based policy think-tank, 84% of the respondents showed willingness to undergo COVID-19 vaccination in India with recommendation by the doctor and evidence on safety being the key influencers to choose the vaccine, at 24% each.
Respondents not willing to take the vaccine cited fears of side effects as the major reason (36%) for not wanting to take the vaccine. A significant share of 42% of the respondents are willing to pay upto INR 500 for the vaccine while another 27% are willing to pay between INR 500-INR 1000. 1mg and BRIEF released the survey findings of the online survey conducted, during in the months of December 2020 and January 2021, across sample size of 30,392 respondents.
The survey assumes importance in light of the recent announcement made during the Union Budget 2021. The Finance Ministry has allocated INR 35,000 crore for COVID-19 vaccine and committed to provide further funds if required. Health and well-being are two of the six crucial pillars that form foundation of the Union Budget this time.
The survey also brought out the key reasons to undertake the COVID-19 vaccination. Living with vulnerable family members at 28% and frequently visiting public places at 22% were the topmost reasons for showing willingness towards undergoing COVID-19 vaccination. The need to stay updated and aware about the latest information on COVID-19 vaccination process in India was seen as holding paramount importance among majority of the respondents at 74%.
Key Findings
1. Willingness for Vaccination
84% of respondents say they are willing to be immunized against COVID-19. Of this group, 28% were living with their family members who are vulnerable, either in terms of their age or have comorbidities; 22% needed to frequently visit public places.
2. Vaccine Selection:
Amongst respondents who expressed willingness to take the COVID vaccine, key influencing factors were Recommendation of the Doctor (24%) and Research evidence on safety (24%).
3. Vaccine Concerns
Primary concern is side effects: 36% of the respondents who did not want to take the vaccine feared potential side-effects.
4. Pricing Perspective
42% of the respondents are willing to spend up to Rs. 500 and 27% are willing to spend uptoRs 1000
5. Other Expectations
74% of the respondents expressed they would like to stay updated on the latest information pertaining to the vaccination process.
Prashant Tandon, CEO-1mg said:
“As India, and the world, embark on the largest vaccination program ever conducted, it is important to understand the perceptions of the citizens who are getting swamped with multiple types of information of all kinds. An efficient program of vaccination requires consumers concerns to be understood and systematically addressed. This survey brings out the primary perceptions towards vaccination as of Jan 2021, which is expected to evolve as the program progresses”.
AfaqHussain, Director-BRIEF said:
“The insights from the pilot survey are interesting and build a case for delving deeper into the perceptions of the people towards COVID-19 vaccination which can support in creating an effective communication strategy, addressing the fears of people and ensuring a smooth vaccination program in India”.
About 1mg
1mg was started with a simple vision of making healthcare affordable, accessible and understandable. With over 37 million app downloads, 345 million monthly page views and >160 million annual unique users visiting the platform, 1mg has made its mark across the country for being a pioneer in the digital healthcare space and is one of the most-trusted player in the segment. 1mg operates India’s largest and integrated digital healthcare platform where e-pharmacy, e-diagnostics and e-consult services are available to customers at the safety of their doorsteps. In recent times, 1mg has played a pivotal role in ensuring that the much-needed healthcare services continue to remain accessible to families right from their homes even amidst the pandemic.
About BRIEF:
Bureau of Research on Industry and Economic Fundamentals (BRIEF) is a New Delhi based research and policy think tank with a focus on international trade and regional cooperation in South Asia. Over the years, BRIEF have partnered with various academia, research institutions, policy groups, think tanks and multilateral institutions to undertake primary survey based research as well as contribute towards policy making and implementation at a domestic and regional level.
It functions as a research partner to institutions such as The World Bank, Foreign, Commonwealth & Development Office (FCDO) UK, The Asia Foundation, Federation of Indian Chambers of Commerce and Industry (FICCI), Confederation of Indian Industry (CII), among others. It has also worked consistently with different departments of the Government of India.
